Equities

Obio Technology Shanghai Corp Ltd

688238:SHH

Obio Technology Shanghai Corp Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)3.91
  • Today's Change-0.14 / -3.46%
  • Shares traded5.90m
  • 1 Year change-60.47%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments6531,221615
Total Receivables, Net18313976
Total Inventory816644
Prepaid expenses6.476.715.67
Other current assets, total4.06334.06
Total current assets9271,465744
Property, plant & equipment, net1,425810345
Goodwill, net------
Intangibles, net555152
Long term investments1074216
Note receivable - long term------
Other long term assets------
Total assets2,6032,4961,263
LIABILITIES
Accounts payable22911950
Accrued expenses212116
Notes payable/short-term debt000
Current portion long-term debt/capital leases181311
Other current liabilities, total463360
Total current liabilities314187137
Total long term debt17379154
Total debt19192165
Deferred income tax5.045.89--
Minority interest0.12----
Other liabilities, total535355
Total liabilities545325346
SHAREHOLDERS EQUITY
Common stock647493393
Additional paid-in capital1,4451,585471
Retained earnings (accumulated deficit)(35)9354
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.370.00--
Total equity2,0582,172918
Total liabilities & shareholders' equity2,6032,4961,263
Total common shares outstanding647641641
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.